Developing a pipeline of novel candidates focused on unmet medical needs for patients

Our Science

At DeepCure, we are focused on discovering and developing novel small-molecule drugs focused on areas of unmet medical need.

Our technology is indication-agnostic, which gives us the unique advantage of being opportunistic with our target selection strategy. Our first step in identifying targets with the best fit was to decide on unmet medical need and unlocking unexplored chemical space, allowing for multi-parameter optimization.

We are developing multiple pipeline candidates across different “undruggable” classes, ranging from polypharmacology programs, to protein-protein interactions, and previously “impossible” specificity challenges.

Early Discovery

Late Discovery




Solid tumors
Inflammatory indications

Late Discovery

DNA Damage Response

Ovarian Cancer
Pancreatic Cancer

Late Discovery

Cell Death Regulation

Hematological Cancers
Early Discovery

Polypharmacology A

Non-Hodgkin’s Lymphoma

Early Discovery

Polypharmacology B

Clear-Cell Ovarian Cancer
Pancreatic Ductal Adenocarcinoma

Early Discovery